Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment

Trial Profile

Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications CNS cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 05 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 10 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top